Making an early link between cognitive impairment and Alzheimer’s

Posted: 5 September 2018 | | No comments yet

Researchers in the U.S. have devised a novel strategy to effectively identify those individuals with mild cognitive impairment that will most likely go on to develop Alzheimer’s disease.

Alzheimer’s cognitive impairment

The research study – led by David Loewenstein, PhD, director of the Center for Cognitive Neuroscience and Aging (CNSA) and professor of psychiatry and behavioural sciences at the University of Miami Miller School of Medicine, alongside co-author Rosie E. Curiel, PsyD, assistant professor of psychiatry and clinical neuropsychology, and colleagues – assessed 88 patients with amnestic mild cognitive impairment (aMCI).

They identified 34 people in this cohort with underlying, prodromal Alzheimer’s disease (AD) by history and amyloid positive scans. Amyloid-beta is an abnormal protein in the brain long associated with the development of AD.

Among the other 54 aMCI participants that were negative for amyloid-beta, 29 were classified as having a clinical course suggestiveof AD but suspected non-AD pathology, or ‘SNAP’. The remaining 25 amyloid negative patients had major depression, anxiety or other psychiatric disorders: cerebral infarctions; diffuse Lewy Body disease; or other non-AD neurologic conditions.

By using a tool developed at the University of Miami – the Loewenstein-Acevedo Scales for Semantic Interference and Learning (LASSI-L) – the team was able to predict those at greatest risk of developing AD by uncovering specific memory deficits that aligned with imaging findings for abnormal brain amyloid accumulation.

Commenting on the value of early detection of AD, Loewenstein said: “Developing more sensitive and effective measures to tap the earliest Alzheimer’s changes in the brain is essential for providing earlier and more effective treatment, to better understand the neuropathology of the disease, and to monitor emerging interventions”.

The LASSI-L measure is a novel “cognitive stress test” validated in both English and Spanish. Researchers ask patients to read 15 words from three categories – fruits, musical instruments and articles of clothing – of five words each. They ask participant to repeat the list of words, and then cue their recall by category. A second trial repeats this learning task and the cued recall to strengthen their recall.

Researchers then present a list of 15 different words from the same three categories. The patients are asked to recall these new words as a measure of proactive semantic interference (PSI). PSI occurs where there is interference in new learning based on previous learning and correlates with risk of developing AD.

Researchers also present the second word list a second time, and repeat the cued recall. This component of the LASSI-L measures how well people can recover from the proactive semantic interference. It’s called failure to recover from PSI (frPSI) and represents a second indicator of AD risk.

A major finding outlined in the Neurology paper was that the amyloid-beta imaging-positive patients committed a significantly higher number of semantic intrusion errors – specifically on the PSI and frPSI measures – compared to the SNAP and other non-AD patients.

Traditional cognitive measures to identify AD risk do not include PSI or frPSI, so the LASSI-L may represent a specific, non-invasive test that could successfully differentiate true AD from SNAP, the researchers noted.

“The association of the LASSI-L with amyloid positivity makes it useful in the clinical evaluation of preclinical Alzheimer’s disease and for appropriate recruitment for clinical and prevention trials,” Loewenstein said.

“This also provides an effective and inexpensive way of screening at-risk populations.”

The research is ongoing. Curiel received a new federal grant to computerise the LASSI-L and other novel cognitive measures. In addition, current studies are underway to compare progression on the LASSI-L to brain biomarkers such as MRI, fMRI and PET scans, as well as new agents that assess pathology in the brain.

“We are assisting our national and international institutional partners in developing this cognitive stress test for their investigations and clinical practice,” Loewensteinsaid. “It is a goal of our Center for Cognitive Neurosciences and Aging and the University of Miami Miller School of Medicine to be at the forefront of these efforts.”

The study, “Utilizing Semantic Intrusions to Identify Amyloid Positivity in Mild Cognitive Impairment,” funded by the National Institute on Aging, was published in Neurology.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.